Resource Center
FOR PHARMCEUTICAL MANUFACTURERS
Medicare Part D Inflation Rebates: January 9 Deadline Approaching
Medicare Part D Inflation Rebates: January 9 Deadline Approaching As the January 9 deadline for Medicare Part D Inflation Rebates approaches, drug manufacturers are entering one of the most consequential compliance checkpoints introduced under the Inflation Reduction...
2026 CMS Final Rule: Expanded ASP Reporting and Verification Requirements for Manufacturers
2026 CMS Final Rule: Expanded ASP Reporting and Verification Requirements for Manufacturers On November 5, 2025, CMS released the Calendar Year 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare...
Pharma Executives’ Guide to 2025: U.S. Drug Tariffs, TrumpRx, and Manufacturing Shifts
Pharma Executives’ Guide to 2025: U.S. Drug Tariffs, TrumpRx, and Manufacturing ShiftsThe Trump administration’s latest policy signals could mark a significant change for the pharmaceutical sector - combining the threat of sweeping tariffs on branded drugs with the...
Medicare Part D Inflation Rebates: January 9 Deadline Approaching
Medicare Part D Inflation Rebates: January 9 Deadline Approaching As the January 9 deadline for Medicare Part D Inflation Rebates approaches, drug manufacturers are entering one of the most consequential compliance checkpoints introduced under the Inflation Reduction...
2026 CMS Final Rule: Expanded ASP Reporting and Verification Requirements for Manufacturers
2026 CMS Final Rule: Expanded ASP Reporting and Verification Requirements for Manufacturers On November 5, 2025, CMS released the Calendar Year 2026 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment and Coverage Policies; Medicare...
Pharma Executives’ Guide to 2025: U.S. Drug Tariffs, TrumpRx, and Manufacturing Shifts
Pharma Executives’ Guide to 2025: U.S. Drug Tariffs, TrumpRx, and Manufacturing ShiftsThe Trump administration’s latest policy signals could mark a significant change for the pharmaceutical sector - combining the threat of sweeping tariffs on branded drugs with the...
Baseline AMP: Guide to Compliance & Profitability
For pharmaceutical manufacturers, a comprehensive understanding of the Baseline Average Manufacturer Price (AMP) is crucial. Its establishment and calculation significantly impact profitability, compliance and long-term value of your product. In this white paper,...
Navigating Texas Medicaid Formulary: Guide for Pharma Mfrs
NAVIGATING THE TEXAS MEDICAID FORMULARY: A Comprehensive Guide for Pharmaceutical ManufacturersThe landscape of pharmaceutical product listing in Texas presents unique challenges for manufacturers seeking Medicaid coverage. Unlike other states, Texas operates its own...
Chargeback Processing: Best Practices to Avoid Revenue Loss
Chargeback Processing — Best Practices to Avoid Revenue Leakage & RiskChargeback processing, validation, and reconciliation are integral in maintaining a profitable business in the highly competitive U.S. pharmaceutical market. Profit margins are tight, especially...
Professor Jeremy’s
KEY TERMS
FOR PHARMA EXECUTIVES
Pharmaceutical professionals often face challenges with the industry’s language, acronyms, and key players. This glossary offers an overview of essential terms every executive should know.